Comorbidity-Polypharmacy Score

There are 8 papers on Comorbidity-Polypharmacy Score in aging research: 8 observational studies in people.

Biomarker

8 papers study it4 more mention it13 findings

See all 12 papers on Comorbidity-Polypharmacy Score

“multiple linear regression analysis revealed that the CPS was independently associated with the BI efficiency (β = -0.100, 95% CI: -0.040, -0.029; P < 0.001)”
Impact of the Comorbidity Polypharmacy Score on Clinical Outcome in Patients with Hip Fracture undergoing surgery Using Real-World DataAnnals of clinical epidemiology2023doi:10.37737/ace.23012
  • Humans8

Interventions

4

Walking outdoors

downin humans1OR 0.6

1 study
  1. Walking outdoors are linked with lower Comorbidity-Polypharmacy Score in humans (age- and sex-adjusted) (OR 0.60, 95% CI 0.42-0.86).

    Humansage- and sex-adjusted

More on Walking outdoors

Fruits

downin humans1OR 0.63

1 study
  1. Fruits are linked with lower Comorbidity-Polypharmacy Score in humans (adjusted for age, sex, body mass index, physical activity and cognitive status) (OR 0.63, 95% CI 0.41-0.97).

    Humansadjusted for age, sex, body mass index, physical activity and cognitive status

More on Fruits

Leafy green vegetables

downin humans1OR 0.54

1 study
  1. Leafy green vegetables are linked with lower Comorbidity-Polypharmacy Score in humans (adjusted for age, sex, body mass index, physical activity and cognitive status) (OR 0.54, 95% CI 0.33-0.87).

    Humansadjusted for age, sex, body mass index, physical activity and cognitive status

More on Leafy green vegetables

Cruciferous vegetables

downin humans1OR 0.56

1 study
  1. Cruciferous vegetables are linked with lower Comorbidity-Polypharmacy Score in humans (adjusted for age, sex, body mass index, physical activity and cognitive status) (OR 0.56, 95% CI 0.35-0.90).

    Humansadjusted for age, sex, body mass index, physical activity and cognitive status

More on Cruciferous vegetables

Effects

3

Length of hospital stay

upin humans1

1 study
  1. Comorbidity-Polypharmacy Score is linked with higher length of hospital stay in humans (hip fracture undergoing surgery) (β = 0.047, 95% CI: 0.199, 0.366, P < 0.001).

    Humanship fracture undergoing surgeryn = 11,564

Barthel Index efficiency

downin humans1

1 study
  1. Comorbidity-Polypharmacy Score is linked with lower Barthel Index efficiency in humans (hip fracture undergoing surgery) (β = -0.100, 95% CI: -0.040, -0.029, P < 0.001).

    Humanship fracture undergoing surgeryn = 11,564

More on Barthel Index efficiency

Mortality

no changein humans1

1 study
  1. Comorbidity-Polypharmacy Score was not clearly linked with mortality in humans.

    Humans

Associations

6

30-day mortality

upin humans1

1 study
  1. Comorbidity-Polypharmacy Score predicts 30-day mortality in humans (mixed ICU population) (AUROC 0.75 (95% CI 0.69 to 0.81)).

    Humansmixed ICU population30-dayn = 319

Discharge to a long-term care facility

upin humans1

1 study
  1. Comorbidity-Polypharmacy Score predicts discharge to a long-term care facility in humans (traumatic injuries (ISS ≥ 9)) (aOR 1.60, 95% CI 1.10-2.32).

    Humanstraumatic injuries (ISS ≥ 9)n = 4,522

Discharge to a rehabilitation facility

upin humans1

1 study
  1. Comorbidity-Polypharmacy Score predicts discharge to a rehabilitation facility in humans (traumatic injuries (ISS ≥ 9)) (aOR 1.72, 95% CI 1.43-2.07).

    Humanstraumatic injuries (ISS ≥ 9)n = 4,522

Mortality

upin humans1

1 study
  1. Comorbidity-Polypharmacy Score is linked with a higher risk of mortality in humans (traumatic injuries (ISS ≥ 9)) (aOR 1.88; 95% CI 1.23-2.89).

    Humanstraumatic injuries (ISS ≥ 9)n = 4,522

Age

upin humans1

1 study
  1. Age is associated with Comorbidity-Polypharmacy Score in humans (p < 0.001).

    Humansn = 648

Overall survival

downin humans1HR 1.11

1 study
  1. Comorbidity-Polypharmacy Score is associated with overall survival in humans (HPV-positive patients) (HR 1.11 in HPV-positive cohort; HR 1.05 in entire cohort (P=.05)).

    HumansHPV-positive patientsn = 117

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months

See all 12 papers on Comorbidity-Polypharmacy Score